Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2018 1
2020 3
2021 3
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Networks of microstructural damage predict disability in multiple sclerosis.
Colato E, Prados F, Stutters J, Bianchi A, Narayanan S, Arnold DL, Wheeler-Kingshott C, Barkhof F, Ciccarelli O, Chard DT, Eshaghi A. Colato E, et al. Among authors: stutters j. J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):992-1003. doi: 10.1136/jnnp-2022-330203. Epub 2023 Jul 19. J Neurol Neurosurg Psychiatry. 2023. PMID: 37468305
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
John NA, Solanky BS, De Angelis F, Parker RA, Weir CJ, Stutters J, Carrasco FP, Schneider T, Doshi A, Calvi A, Williams T, Plantone D, Monteverdi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS-SMART Investigators. John NA, et al. Among authors: stutters j. J Magn Reson Imaging. 2023 Oct 3. doi: 10.1002/jmri.29017. Online ahead of print. J Magn Reson Imaging. 2023. PMID: 37787109
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Among authors: stutters j. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Remyelination varies between and within lesions in multiple sclerosis following bexarotene.
Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, Jones JL, Georgieva ZG, Needham EJ, Daruwalla C, Wheeler-Kingshott CG, Connick P, Chandran S, Franklin R, MacManus D, Samson R, Coles A, Chard D. Brown JWL, et al. Among authors: stutters j. Ann Clin Transl Neurol. 2022 Oct;9(10):1626-1642. doi: 10.1002/acn3.51662. Epub 2022 Sep 17. Ann Clin Transl Neurol. 2022. PMID: 36116011 Free PMC article.
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT.
De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados F, Marshall I, Solanky B, Samson RS, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Gnanapavan S, Giovannoni G, Wheeler-Kingshott CAMG, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J. De Angelis F, et al. Among authors: stutters j. Southampton (UK): NIHR Journals Library; 2020 May. Southampton (UK): NIHR Journals Library; 2020 May. PMID: 32453521 Free Books & Documents. Review.
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
Colato E, Stutters J, Tur C, Narayanan S, Arnold DL, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O, Chard DT, Eshaghi A. Colato E, et al. Among authors: stutters j. J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):995-1006. doi: 10.1136/jnnp-2020-325610. Epub 2021 Apr 20. J Neurol Neurosurg Psychiatry. 2021. PMID: 33879535 Free PMC article. Clinical Trial.
Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
Calvi A, Tur C, Chard D, Stutters J, Ciccarelli O, Cortese R, Battaglini M, Pietroboni A, De Riz M, Galimberti D, Scarpini E, De Stefano N, Prados F, Barkhof F. Calvi A, et al. Among authors: stutters j. Neuroimage Clin. 2022;35:103048. doi: 10.1016/j.nicl.2022.103048. Epub 2022 May 16. Neuroimage Clin. 2022. PMID: 35598462 Free PMC article.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Hartung HP, et al. Among authors: stutters j. Mult Scler. 2022 Mar;28(3):429-440. doi: 10.1177/13524585211024997. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240656 Free article. Clinical Trial.
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
Calvi A, Carrasco FP, Tur C, Chard DT, Stutters J, De Angelis F, John N, Williams T, Doshi A, Samson RS, MacManus D, Gandini Wheeler-Kingshott CA, Ciccarelli O, Chataway J, Barkhof F; MS SMART Investigators. Calvi A, et al. Among authors: stutters j. Neurology. 2022 Apr 26;98(17):e1783-e1793. doi: 10.1212/WNL.0000000000200144. Epub 2022 Mar 11. Neurology. 2022. PMID: 35277438
16 results